Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.

Abstract

BACKGROUND:

Our aim was to investigate the prognostic and predictive value of the oncogenic MAPKK-like protein T-cell-originated protein kinase (TOPK) stratified by KRAS and BRAF mutations in patients with sporadic, hereditary and metastatic colorectal cancer (CRC) treated with anti-EGFR therapy.

METHODS:

Immunohistochemistry (IHC) for TOPK was performed on four study groups. Group 1 included two subgroups of 543 and 501 sporadic CRC patients used to test the reliability of TOPK expression by IHC. In Group 2, representing an additional 222 sporadic CRCs, the prognostic effect of TOPK stratified by KRAS and BRAF was assessed. The prognostic effect of TOPK was further analysed in Group 3, representing 71 hereditary Lynch syndrome-associated CRC patients. In Group 4, the predictive and prognostic value of TOPK was analysed on 45 metastatic patients treated with cetuximab or panitumumab stratified by KRAS and BRAF gene status.

RESULTS:

In both sporadic CRC subgroups (Group 1), associations of diffuse TOPK expression with clinicopathological features were reproducible. Molecular analysis of sporadic CRCs in Group 2 showed that diffuse TOPK expression was associated with KRAS and BRAF mutations (p<0.001) and with poor outcome in patients with either mutation in univariate and multivariate analysis (P=0.017). In hereditary patients (Group 3), diffuse TOPK was linked to advanced pT stage. In metastatic patients treated with anti-EGFR therapy (Group 4), diffuse TOPK expression was linked to dismal outcome despite objective response to treatment (P=0.01).

CONCLUSIONS:

TOPK expression is an unfavourable prognostic indicator in sporadic patients with KRAS or BRAF mutations and also in patients with metastatic disease experiencing a response to anti-EGFR therapies. The inhibition of TOPK, which could benefit 30-40% of CRC patients, may represent a new avenue of investigation for targeted therapy.

• Authors: I Zlobec, F Molinari, M Kovac, M P Bihl, H J Altermatt, J Diebold, H Frick, M Germer, M Horcic, M Montani, G Singer, H Yurtsever, A Zettl, L Terracciano, L Mazzucchelli, P Saletti, M Frattini, K Heinimann, A Lugli
• Journal: British journal of cancer (Br J Cancer) Vol. 102 Issue 1 Pg. 151-61 (Jan 05 2010) ISSN: 1532-1827 [Electronic] England
• PMID: 19935791 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Protein Kinase Inhibitors
• Panitumumab
• EGFR protein, human
• ErbB Receptors
• BRAF protein, human
• Protein Serine-Threonine Kinases
• Proto-Oncogene Proteins B-raf
• Mitogen-Activated Protein Kinase Kinases
• PDZ-binding kinase
• Cetuximab

Topics

• Adenocarcinoma (chemistry, drug therapy, epidemiology, genetics, secondary)
• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal (pharmacology, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents (pharmacology, therapeutic use)
• Cetuximab
• Colorectal Neoplasms (chemistry, drug therapy, epidemiology, genetics, pathology)
• Colorectal Neoplasms, Hereditary Nonpolyposis (chemistry, epidemiology, genetics, pathology)
• ErbB Receptors (antagonists & inhibitors, immunology)
• Female
• Follow-Up Studies
• Gene Expression Regulation, Neoplastic
• Genes, ras
• Humans
• Male
• Middle Aged
• Mitogen-Activated Protein Kinase Kinases
• Observer Variation
• Panitumumab
• Predictive Value of Tests
• Prognosis
• Protein Kinase Inhibitors (pharmacology, therapeutic use)
• Protein Serine-Threonine Kinases (analysis)
• Proto-Oncogene Proteins B-raf (genetics)
• Random Allocation
• Reproducibility of Results
• Signal Transduction (genetics)